hier eine sehr interessante Biotechaktie mit einer noch interessanteren Pipeline

http://www.redhillbio.com/products

RHB-105 - A combination therapy for Helicobacter pylori infection, with successful top-line results from a first Phase III study.

RHB-104 – A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway, and for multiple sclerosis, with a Phase IIa proof of concept study underway.

BEKINDA™ (RHB-102) – A once-daily oral pill formulation of ondansetron, with a Phase III study underway in the U.S. for acute gastroenteritis and gastritis and a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting submitted to the UK MHRA in December 2014.

RHB-106 – An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.

ABC294640 – A Phase II-stage orally-administered SK2 inhibitor targeting multiple inflammatory-GI diseases and related oncology indications

MESUPRON® – A Phase II uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers.

RP101 –  A Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers, currently subject to an option-to-acquire by RedHill.

RIZAPORT™ (RHB-103) – An oral thin film formulation of rizatriptan, for the treatment of acute migraines, with a U.S. NDA under review by the FDA and a European marketing application submitted to the German BfArM in October 2014.

link für die Presentation:

http://ir.redhillbio.com

link für die News:

http://www.redhillbio.com/news-2015

 

gestern die News zur KE 16,25$ kam, hab ich mir die erste Position gegönnt...


http://www.redhillbio.com/RedHill/Templates/...amp;PID=0&IID=1958



 

hier um RedHill Bio....leider ist der Thread falsch verlinkt..


habe es selber den Mods gemeldet, mal schauen ob Sie das können...  

raised to 30$


http://www.streetinsider.com/Analyst+Comments/...apital/10651512.html  

von 23$ auf 32$ erhöht


http://www.finanzen.net/analyse/...rma_Buy-H_C_Wainwright__Co__541876  

Planned Near-Term Milestones


Our key research and development milestones for 2015/2016 are the following:

Q3/2015


          
RHB-105:§
   
Final clinical study report (CSR) from the first Phase III study of RHB-105 (Q3)
   
Planned meeting with FDA to discuss design for pivotal study, clinical and regulatory path towards approval in the U.S. (Q3-Q4)
   
 

ABC294640:
   
First patient enrolled in the Phase I/II study with ABC294640 for refractory/relapsed diffuse large B cell lymphoma
   


H2/2015 –H1/2016

          
RHB-104:§
   
Top-line interim results from Phase IIa study for multiple sclerosis (Q4/15-Q1/16)
   


BEKINDA™ (formerly RHB-102):
   
Top-line results from Phase III study in gastroenteritis and gastritis (Q4/15-Q1/16)

Feedback from UK MHRA regarding European marketing application for oncology support (H1/2016)

Initiation of Phase IIa study for new undisclosed indication (H2/15)

   
 
RIZAPORT™ (formerly RHB-103):

   
Feedback from Germany’s BfArM regarding the European marketing application for migraines (Q3-Q4/2015)

A new PDUFA date expected from the FDA for previously filed NDA





Financial Update

While we have not finalized our full financial results for the six month period ending June 30, 2015, we had approximately $27 million of cash, cash equivalents and short-term investments as of June 30, 2015. Our current cash resources are not sufficient to complete the research and development of all of our therapeutic candidates.


http://ih.advfn.com/p.php?pid=nmona&article=67768459  

nach Offering



Total Ordinary Shares outstanding immediately after this offering
          §  
124,224,114 Ordinary Shares (127,917,114 Ordinary Shares if the underwriters exercise their over-allotment option in full).


The ADSs
          §  
Each ADS represents 10 Ordinary Shares. The ADSs initially will be evidenced by American Depositary Receipts (“ADRs”), executed and delivered by The Bank of New York Mellon, as Depositary.

 

seid herzlich eingeladen hier.....



vielleicht sind ja einige von euch auch hier schon drin, könnt euch gerne

ja kenntlich zeigen ;-)



und eure Meinung zur dieser Perle kundtun


Chartisten und Biotechpofis sind natürlich sehr wertvoll für so einen Thread,


also haltet euch nicht zurück :-)  

leider zu Kursen von 19$...
Aber Redhill geht seinen Weg!  

Offering abgeschlossen

http://money.cnn.com/news/newsfeeds/articles/...newswire/10142614.htm  

Investors in the offering included Broadfin Capital LLC, Visium Asset Management, Special Situations Funds, funds managed by Sabby Management LLC, Longwood Capital Partners LLC, Menora Mivtachim and others.  

 

abgeschlossen !!  

sich doch sehr gut heute im Vergleich zum
Gesamtmarkt und das trotz einer ke  

der Zahlen und Conference Call



The Company will also host a conference call on Wednesday, July 29, 2015, at 9:00 am EDT to review the financial results and business highlights



http://money.cnn.com/news/newsfeeds/articles/...newswire/10142789.htm  

nicht allzu toll...
Gut Ding hat Weile ;-)  

RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals



http://www.streetinsider.com/SEC+Filings/...r%3A+Jul+27/10751022.html  

-5% ist schon wieder krass...
Wieso jetzt nur noch down???  

ich hatte doch schon einen Thread mit den Infos erstellt. Es reicht doch, wenn die Infos in einem Thread gepostet werden...  

Habe einen gesucht und leider nicht gefunden....sonst hätte ich den nicht aufgemacht...leider klappt das mit dem verlinken hier nicht und die mods interessiert das auch nicht....  

Key Highlights Include:

Strong cash position of

... (automatisch gekürzt) ...

http://www.redhillbio.com/RedHill/Templates/...amp;PID=0&IID=1966

 

kennt ja gar kein Grünen Tag mehr :-/  

sorry, aber hast du mal dir auch den Gesamtmarkt angeschaut !?

 

für RDHL?  

http://www.streetinsider.com/Corporate+News/...+RHB-104/10847450.html